Ticker > Company >

Jubilant Pharmova share price

Jubilant Pharmova Ltd.

NSE: JUBLPHARMA BSE: 530019 SECTOR: Pharmaceuticals & Drugs  143k   496   89

1094.20
-31.40 (-2.79%)
NSE: 13 Jun 04:14 PM

Price Summary

Today's High

₹ 1174.4

Today's Low

₹ 1060

52 Week High

₹ 1309.9

52 Week Low

₹ 701.8

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyPoor
The company seems highly inefficient in case of asset management.
FinancialsWeak
Watch out! The company might not be able to sustain any adverse condition.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

17428.54 Cr.

Enterprise Value

17735.34 Cr.

No. of Shares

15.93 Cr.

P/E

907.75

P/B

7.52

Face Value

₹ 1

Div. Yield

0.46 %

Book Value (TTM)

₹  145.54

CASH

36.1 Cr.

DEBT

342.9 Cr.

Promoter Holding

50.68 %

EPS (TTM)

₹  1.21

Sales Growth

-3.14%

ROE

1.32 %

ROCE

2.64%

Profit Growth

-36.67 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year-3.14%
3 Year-33.84%
5 Year-25.58%

Profit Growth

1 Year-36.67%
3 Year-47.18%
5 Year-26.53%

ROE%

1 Year1.32%
3 Year2.57%
5 Year6.34%

ROCE %

1 Year2.64%
3 Year3.56%
5 Year6.52%

Debt/Equity

0.1452

Price to Cash Flow

121.71

Interest Cover Ratio

2.3946

CFO/PAT (5 Yr. Avg.)

1.43301682320157

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Mar 2025 50.68 0.00
Dec 2024 50.68 0.00
Sep 2024 50.68 0.00
Jun 2024 50.68 0.00
Mar 2024 50.68 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has an efficient Cash Conversion Cycle of 59.765 days.
  • The company has a good cash flow management; CFO/PAT stands at 1.43301682320157.
  • The company has a high promoter holding of 50.68%.
  • The company has a strong degree of Operating leverage, Average Operating leverage stands at 3.24980529856399.

 Limitations

  • The company has shown a poor profit growth of -47.18343712341% for the Past 3 years.
  • The company has shown a poor revenue growth of -33.8382881923691% for the Past 3 years.
  • Company has a poor ROE of 2.56951664282011% over the past 3 years.
  • Company has a poor ROCE of 3.55591725790731% over the past 3 years
  • The company is trading at a high PE of 907.75.
  • The company is trading at a high EV/EBITDA of 134.5577.

Quarterly Result (All Figures in Cr.)

PARTICULARS Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025
Net Sales 205.8 166.7 165.7 196 217.3
Total Expenditure 193.6 165.5 171.8 185 191.3
Operating Profit 12.2 1.2 -6.1 11 26
Other Income 50.1 19.5 43.8 18.4 17.9
Interest 8.1 7.6 7.8 7.4 7
Depreciation 12.7 13.1 13.3 13.3 13.4
Exceptional Items 0 -11.2 0 0 0
Profit Before Tax 41.5 -11.2 16.6 8.7 23.5
Tax 9 -1 6.1 3.4 9.9
Profit After Tax 32.5 -10.2 10.5 5.3 13.6
Adjusted EPS (Rs) 2.04 -0.64 0.66 0.33 0.86

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Net Sales 3139.9 2709.5 725.73 810.1 784.7
Total Expenditure 2769 2282.44 719.27 807 768.2
Operating Profit 370.9 427.06 6.46 3.1 16.5
Other Income 173.23 47.88 126.16 137.9 103.4
Interest 136.2 101.8 10.99 18.5 29.9
Depreciation 107.4 99.97 36.91 43.2 48.3
Exceptional Items -1.7 0 0 0 0
Profit Before Tax 298.84 273.17 84.72 79.3 41.7
Tax -22.3 58.69 4.23 29.4 10.1
Net Profit 321.14 214.48 80.49 49.9 31.6
Adjusted EPS (Rs.) 20.16 13.47 5.05 3.14 1.99

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity and Liabilities
Share Capital 15.93 15.93 15.93 15.9 15.9
Total Reserves 2591.37 1266.52 2423.14 2398.6 2358.6
Borrowings 1327.91 420 174 174 246.5
Other N/C liabilities 122.95 22 -5.1 41.7 43.6
Current liabilities 1375.23 120.15 252.26 361.2 315.4
Total Liabilities 5433.39 1844.6 2860.23 2991.4 2980
Assets
Net Block 1864.72 127.08 636.51 687.4 711.3
Capital WIP 58.41 0.33 35.26 47 37
Intangible WIP 0.68 0 0 0 0
Investments 1764.03 1645.98 1645.75 1656.6 1656.9
Loans & Advances 16.03 4.96 13.98 18.6 24.3
Other N/C Assets 7.39 0 2.92 3 9.9
Current Assets 1722.13 66.25 525.81 578.8 540.6
Total Assets 5433.39 1844.6 2860.23 2991.4 2980
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Profit from operations 298.84 273.17 84.72 79.3 41.7
Adjustment 103.01 196.45 -48.68 -35.2 48.2
Changes in Assets & Liabilities -65.06 181.36 -3.42 -91.8 65.5
Tax Paid -20.03 -42.6 -19.38 -17.4 -12.2
Operating Cash Flow 316.76 608.38 -3.55 -65.1 143.2
Investing Cash Flow -197.71 116.89 93.1 31.1 -40.3
Financing Cash Flow -41.05 -781.65 -107.37 22.5 -77.8
Net Cash Flow 78 -56.37 -17.82 -11.5 25.1

Corporate Actions

Investors Details

PARTICULARS Mar 2024% Jun 2024% Sep 2024% Dec 2024% Mar 2025%
promoters 50.68 50.68 50.68 50.68 50.68
hari shanker bhartia 0.23 0.23 0.23 0.23 0.23
hsb trustee company pvt l... 19.00 19.00 19.00 19.00 19.00
jubilant enpro private li... 1.33 1.33 1.33 1.33 1.33
kavita bhartia 0.01 0.01 0.01 0.01 0.01
mav management advisors l... 3.15 3.15 3.15 3.15 3.15
miller holdings pte ltd 3.28 3.28 3.28 3.28 3.28
nikita resources private ... 2.20 2.20 2.20 2.20 2.20
priyavrat bhartia 0.88 0.88 0.88 0.88 0.88
shamit bhartia 0.08 0.08 0.08 0.08 0.08
spb trustee company pvt l... 20.52 20.52 20.52 20.52 20.52
PARTICULARS Mar 2024% Jun 2024% Sep 2024% Dec 2024% Mar 2025%
investors 49.32 49.32 49.32 49.32 49.32
abakkus emerging opportun... 1.20 1.20 1.20 1.20 1.18
east bridge capital maste... 3.17 3.17 4.88 3.92 4.30
government pension fund g... 3.76 3.75 3.71 3.45 3.47
investor education and pr... 1.24 1.24 1.24 - 1.25
llp - - 0.27 0.28 0.21
quant mutual fund - quant... - 1.92 1.92 1.92 1.85
rekha jhunjhunwala 6.64 6.57 6.43 3.15 6.43
sbi life insurance co. lt... - - - 1.39 1.32
theleme india master fund... 1.17 1.37 1.33 1.32 1.46
estate of late mr. rakesh... - - - 3.28 -
investor education and pr... - - - 1.25 -
non resident non repartri... - - 0.74 - -
east bridge capital maste... 4.27 4.18 - - -
quant mutual fund - quant... 1.75 - - - -

Annual Reports

Title Action
Annual Report 2024
Annual Report 2023
Annual Report 2022
Annual Report 2021
Annual Report 2020
Annual Report 2019
Annual Report 2018
Annual Report 2017
Annual Report 2017

Ratings & Research Reports

TYPE AGENCY ACTION
Credit FITCH
Credit FITCH
Credit CRISIL
Credit CRISIL
Credit CRISIL
Credit CRISIL
Credit INDIA RATINGS & RESEARCH
Credit CRISIL
TYPE AGENCY ACTION
Research Motilal Oswal
Research Nirmal Bang Institutional
Research Prabhudas Lilladhar
Research HDFC Securities

Concalls & Presentations

TYPE QUARTER ACTION
Concall Q4FY22
Concall Q2FY21
Concall Q1FY21
TYPE QUARTER ACTION
Presentation Q4FY25
Presentation Q4FY24
Presentation Q4FY24
Presentation Q4FY21
Presentation Q4FY21
Presentation Q4FY21
Presentation Q3FY25
Presentation Q3FY24
Presentation Q2FY24
Presentation Q2FY21
Presentation Q1FY25
Presentation Q1FY24
Presentation Q1FY24
Presentation Q1FY21

Company News

Jubilant Pharmova Stock Price Analysis and Quick Research Report. Is Jubilant Pharmova an attractive stock to invest in?

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Jubilant Pharmova and its performance over the period of time. Jubilant Pharmova stock price today is Rs 1094.2.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Jubilant Pharmova cash from the operating activity was Rs 143.2 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Jubilant Pharmova has a Debt to Equity ratio of 0.1452 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Jubilant Pharmova , the EPS growth was -36.6747 % which is bad for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Jubilant Pharmova has OPM of 2.10271441315152 % which is a bad sign for profitability.
     
  • ROE: Jubilant Pharmova have a poor ROE of 1.3241 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
     
  • Share Price: - The current share price of Jubilant Pharmova is Rs 1094.2. One can use valuation calculators of ticker to know if Jubilant Pharmova share price is undervalued or overvalued.
Last Updated on:
Brief about Jubilant Pharmova
X